BR112022005575A2 - Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila - Google Patents

Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila

Info

Publication number
BR112022005575A2
BR112022005575A2 BR112022005575A BR112022005575A BR112022005575A2 BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2 BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2
Authority
BR
Brazil
Prior art keywords
enonitrile
oxetan
pent
pyrazolo
piperazin
Prior art date
Application number
BR112022005575A
Other languages
English (en)
Portuguese (pt)
Inventor
Ann Neale
Dolca Thomas
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of BR112022005575A2 publication Critical patent/BR112022005575A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022005575A 2019-10-09 2020-10-08 Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila BR112022005575A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913029P 2019-10-09 2019-10-09
US201962942877P 2019-12-03 2019-12-03
PCT/US2020/054809 WO2021072095A1 (en) 2019-10-09 2020-10-08 Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
BR112022005575A2 true BR112022005575A2 (pt) 2022-06-21

Family

ID=73030241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005575A BR112022005575A2 (pt) 2019-10-09 2020-10-08 Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila

Country Status (13)

Country Link
US (2) US20210106583A1 (es)
EP (1) EP4041240A1 (es)
JP (1) JP2022552199A (es)
KR (1) KR20220079909A (es)
CN (1) CN115190798A (es)
AU (1) AU2020363873A1 (es)
BR (1) BR112022005575A2 (es)
CA (1) CA3153750A1 (es)
CO (1) CO2022005949A2 (es)
IL (1) IL291726A (es)
MX (1) MX2022004283A (es)
TW (1) TW202128172A (es)
WO (1) WO2021072095A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
ES2841248T3 (es) 2014-02-21 2021-07-07 Principia Biopharma Inc Sales y forma sólida de un inhibidor de BTK
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
US20180015088A1 (en) 2014-12-24 2018-01-18 Principia Biopharma Inc. Site specific dosing of a btk inhibitor
KR102515813B1 (ko) 2016-06-29 2023-03-30 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제
JP7331843B2 (ja) * 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤

Also Published As

Publication number Publication date
US20210106583A1 (en) 2021-04-15
CO2022005949A2 (es) 2022-07-29
CN115190798A (zh) 2022-10-14
KR20220079909A (ko) 2022-06-14
TW202128172A (zh) 2021-08-01
CA3153750A1 (en) 2021-04-15
JP2022552199A (ja) 2022-12-15
WO2021072095A1 (en) 2021-04-15
EP4041240A1 (en) 2022-08-17
MX2022004283A (es) 2022-07-12
IL291726A (en) 2022-05-01
AU2020363873A1 (en) 2022-04-14
US20230158033A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
EA202092154A1 (ru) Комбинированная терапия
BR112018008965A2 (pt) terapia de reposição de plasminogênio para deficiência de plasminogênio
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
RU2017134443A (ru) Способ лечения с применением традипитанта
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
EA202290024A1 (ru) Способы лечения болезни фабри у пациентов с почечной недостаточностью
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
EA202190744A1 (ru) Слитый белок glp1-fc и его конъюгат
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112022005575A2 (pt) Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
BR112018008769A2 (pt) formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída
EP4282477A3 (en) Combination comprising sildenafil for use in the treatment of osteoarthritis